Pricing Log in Create free account

ADC Therapeutics SA (ADCT) vs Keros Therapeutics, Inc. (KROS)

ADC Therapeutics SA and Keros Therapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. is the larger, with a market value of $220.1M against $190.2M — 1.2× the size. ADC Therapeutics SA grew revenue faster over the last twelve months: 3.03% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −121.8%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 17 metrics below, Keros Therapeutics, Inc. leads on 11 and ADC Therapeutics SA on 6.

Valuation

Metric ADCT KROS Biotechnology median
P/E n/m n/m 8.42
P/S 2.90 6.62 10.01
P/B n/m 0.84 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m 0.38 0.61
EV/Sales 1.61 (1.14) 9.41
Earnings yield (44.30%) (33.33%) (31.85%)
Free cash flow yield (44.04%) (22.06%) (24.58%)

Profitability

Metric ADCT KROS Biotechnology median
Gross margin 88.86% 100.00% 65.16%
Operating margin (125.08%) 0.00% 0.00%
Net margin (121.77%) 0.00% 0.00%
Free cash flow margin (127.72%) 0.00% 0.00%
Return on equity 45.35% (17.16%) (56.36%)
Return on assets (32.25%) (15.92%) (48.04%)
Return on invested capital 0.00% (1,345.30%) 0.00%

Growth

Metric ADCT KROS Biotechnology median
Revenue growth (TTM) 3.03% (84.55%) 6.02%
EPS growth (last fiscal year) 30.86% 146.00% 30.26%
Revenue growth, 5-year CAGR 103.35% 89.45% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADCT KROS Biotechnology median
Debt to equity (0.51) 0.00 0.00
Current ratio 3.03 21.96 4.72
Net debt to EBITDA 1.22 (4.16) 0.96

Dividend

Metric ADCT KROS Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ADCT KROS Biotechnology median
Market cap 190.23m 220.08m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack